177Lu-labeled NY108 SPECT Imaging in Patients

Inclusion Criteria: Patients voluntarily signed informed consent; Age 18-75, male; Clinical diagnosis of prostate cancer with diagnostic criteria referencing biopsy and at least one metastasis; Patients must be 68Ga-NY108 Positron Emission Tomography (PET)/Computed Tomography (CT) scan positive; Patients must have received at least one NAAD (such as enzalutamide and/or abiraterone) and at least one paclitaxel regimen; Progressive metastatic destructive resistant prostate cancer as determined by PCWG3 criteria; An ECOG score of 0-2 Exclusion Criteria: Recovery from major trauma (including surgery) within 4 weeks prior to study treatment; Patients with severe systemic or localized infections or other serious coexisting diseases; Patients with abnormal immune function or who have recently used immunosuppressive or booster agents including various vaccines, etc; Patients with autoimmune diseases, including rheumatoid, etc; Inadequately controlled arrhythmias, including atrial fibrillation: Cardiac insufficiency (New York Heart Association (NYHA) work class criteria); Uncontrolled hypertension; Patients with a history of allergy or hypersensitivity to any component of the imaging agent, including antibodies; Subjects positive for syphilis, HBV, HCV, FIIV; Subjects of childbearing age who are unable to use effective contraceptive devices: Patients with a history of mental illness or related medical conditions; Patients who are unable or unavailable for SPECT/CT scanning; Other subjects who, in the opinion of the investigator, are not suitable for enrollment.